Literature DB >> 15601437

Plasma clearance.

P L Toutain1, A Bousquet-Mélou.   

Abstract

Plasma (total, systemic...) clearance is determined by all the individual metabolizing/eliminating organ clearances and involves mainly liver and kidney clearances. Plasma clearance (a volume per time, i.e. a flow) expresses the overall ability of the body to eliminate a drug by scaling the drug elimination rate (amount per time) by the corresponding plasma concentration level. The interpretation of plasma clearance and inter-species comparisons are made easier by computing the overall body extraction ratio (from 0 to 1), which is the ratio of the body clearance divided by cardiac output. Plasma clearance is the most important pharmacokinetic parameter because it is the only one which controls the overall drug exposure (for a given bioavailability) and it is the parameter which allows computation of the dosage required to maintain an average steady-state plasma concentration.

Mesh:

Substances:

Year:  2004        PMID: 15601437     DOI: 10.1111/j.1365-2885.2004.00605.x

Source DB:  PubMed          Journal:  J Vet Pharmacol Ther        ISSN: 0140-7783            Impact factor:   1.786


  46 in total

1.  Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous administration in buffalo calves (Bubalus bubalis).

Authors:  Ravinder Sappal; Rakesh Kumar Chaudhary; Harpal Singh Sandhu; Pritam Kaur Sidhu
Journal:  Vet Res Commun       Date:  2009-03-19       Impact factor: 2.459

Review 2.  A Guide to Understanding Antimicrobial Drug Dosing in Critically Ill Patients on Renal Replacement Therapy.

Authors:  Valentina Pistolesi; Santo Morabito; Francesca Di Mario; Giuseppe Regolisti; Chiara Cantarelli; Enrico Fiaccadori
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 3.  Scaffold-hopping as a strategy to address metabolic liabilities of aromatic compounds.

Authors:  Phillip R Lazzara; Terry W Moore
Journal:  RSC Med Chem       Date:  2019-12-16

4.  Evaluating a tylosin dosage regimen for treatment of Staphylococcus delphini infection in mink (Neovison vison): a pharmacokinetic-pharmacodynamic approach.

Authors:  Amir Atabak Ronaghinia; Julie Melsted Birch; Henrik Lauritz Frandsen; Pierre-Louis Toutain; Peter Damborg; Tina Struve
Journal:  Vet Res       Date:  2021-02-27       Impact factor: 3.683

5.  Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.

Authors:  Evelyn L Craig; Bin Zhao; Jason Z Cui; Maria Novalen; Sharon Miksys; Rachel F Tyndale
Journal:  Drug Metab Dispos       Date:  2014-06-30       Impact factor: 3.922

6.  HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.

Authors:  Takuya Osada; Erika J Crosby; Kensuke Kaneko; Joshua C Snyder; Joshua D Ginzel; Chaitanya R Acharya; Xiao-Yi Yang; Thomas J Polascik; Ivan Spasojevic; Rendon C Nelson; Amy Hobeika; Zachary C Hartman; Leonard M Neckers; Andre Rogatko; Philip F Hughes; Jiaoti Huang; Michael A Morse; Timothy Haystead; H Kim Lyerly
Journal:  Mol Cancer Ther       Date:  2021-10-21       Impact factor: 6.261

7.  Pharmacokinetics of combined administration of iron dextran with meloxicam or flunixin meglumine in piglets.

Authors:  Saad S Enouri; Terri L O'Sullivan; Steve Ramkissoon; Robert M Friendship; Yu Gu; Ron J Johnson
Journal:  Can Vet J       Date:  2022-07       Impact factor: 1.075

8.  Aqueous stability and oral pharmacokinetics of meloxicam and carprofen in male C57BL/6 mice.

Authors:  Joelle C Ingrao; Ron Johnson; Elizabeth Tor; Yu Gu; Marcus Litman; Patricia V Turner
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-09       Impact factor: 1.232

9.  Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection.

Authors:  Joe S Smith; David J Borts; Clare C Slagel; Suzanne M Rajewski; Alain Bousquet-Melou; Aude A Ferran; Paul J Plummer; Jon P Mochel
Journal:  Comp Med       Date:  2019-10-03       Impact factor: 0.982

10.  Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics.

Authors:  Laura Molenaar-Kuijsten; Bart Albertus Wilhelmus Jacobs; Sophie Alberdine Kurk; Anne Maria May; Thomas Petrus Catharina Dorlo; Jacob Hendrik Beijnen; Neeltje Steeghs; Alwin Dagmar Redmar Huitema
Journal:  Cancer Med       Date:  2021-06-14       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.